The Society for Immunotherapy of Cancer’s (SITC) 37th Annual Meeting & Pre-Conference Programs (SITC 2022) are taking place Nov. 8–12, 2022, at the Boston Convention and Exhibition Center in Boston. BBCR will be attending the conference this week and is looking forward to reporting back on conference events. Are you attending? Please let us know! […]
Tagged: SITC
BBCR is attending this week’s SITC 37th Annual Meeting & Pre-Conference Program and we will reporting on conference events soon.
November 9th, 2022 | SITCCategories
- Biomarkers & Surrogate Endpoints
- Company News
- Drug Development
- Due Diligence
- Early Clinical Development
- Industry News
- Medical Affairs and Clinical Research
- Miscellaneous
- Orphan Diseases
- Pre-IND
- Precision Medicine
- Rare Disease
- Real World Evidence
- Regulatory
- Regulatory Affairs
- Strategy and TPP
- Translation Medicine and Epigenetics
- Trial Management
- Trial Rescue
Recent Posts
- BBCR assists companies with the identification and adoption of biomarkers, now a routine part of drug development, and especially valuable in rare disease and precision medicine product development. Reach out to us to learn how we can assist with your development project.
- Partnering with BBCR Consulting means gaining the support of a specialized team committed to making the clinical trial process more efficient.
- Who is BBCR and how do we help pharmaceutical innovators in the specialized rare diseases and orphan drug industries? We invite you to learn more at bbcrconsulting.com.
- Accelerate Drug Development with Biomarker Strategy in Orphan Diseases and Precision Medicine
- At BBCR, our team of seasoned experts is dedicated to helping clients navigate the intricate landscape of rare genetic conditions and unsolved diseases. We work hand in hand with product developers to create the most effective strategies for bringing innovative treatments to market.